Published Online:4 May 2012https://doi.org/10.2217/pme.12.15
Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest
References
- 1 Bourne TD, Schiff D. Update on molecular findings, management and outcome in low-grade gliomas. Nat. Rev. Neurol.6(12),695–701 (2010).
- 2 Bromberg JE, Van Den Bent MJ. Oligodendrogliomas: molecular biology and treatment. Oncologist14(2),155–163 (2009).
- 3 Maintz D, Fiedler K, Koopmann J et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J. Neuropathol. Exp. Neurol.56(10),1098–1104 (1997).
- 4 Smith JS, Perry A, Borell TJ et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol.18(3),636–645 (2000).
- 5 Bralten LB, Nouwens S, Kockx C et al. Absence of common somatic alterations in genes on 1p and 19q in oligodendrogliomas. PLoS ONE6(7),E22000 (2011).
- 6 Bettegowda C, Agrawal N, Jiao Y et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science333(6048),1453–1455 (2011).▪▪ First study to identify CIC and FUBP1 as putative tumor suppressor genes likely driving 1p/19q loss in oligodendrogliomas.
- 7 Yip S, Butterfield YS, Morozova O et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J. Pathol.226(1),7–16 (2012).▪▪ Verified that CIC is frequently and specifically mutated in oligodendrogliomas.
- 8 Roch F, Jimenez G, Casanova J. EGFR signalling inhibits capicua-dependent repression during specification of Drosophila wing veins. Development129(4),993–1002 (2002).
- 9 Ajuria L, Nieva C, Winkler C et al. Capicua DNA-binding sites are general response elements for RTK signaling in Drosophila. Development138(5),915–924 (2011).
- 10 Astigarraga S, Grossman R, Diaz-Delfin J, Caelles C, Paroush Z, Jimenez G. A MAPK docking site is critical for downregulation of capicua by Torso and EGFR RTK signaling. EMBO J.26(3),668–677 (2007).
- 11 Lee CJ, Chan WI, Cheung M et al. CIC, a member of a novel subfamily of the HMG-box superfamily, is transiently expressed in developing granule neurons. Brain Res. Mol. Brain Res.106(1–2),151–156 (2002).
- 12 Duncan R, Bazar L, Michelotti G et al. A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev.8(4),465–480 (1994).
- 13 Hsiao HH, Nath A, Lin CY, Folta-Stogniew EJ, Rhoades E, Braddock DT. Quantitative characterization of the interactions among c-myc transcriptional regulators FUSE, FBP, and FIR. Biochemistry49(22),4620–4634 (2010).
- 14 Podar K, Anderson KC. A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. Cell Cycle9(9),1722–1728 (2010).
- 15 Yan H, Parsons DW, Jin G et al.IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med.360(8),765–773 (2009).
- 16 Jenkinson MD, Walker C, Brodbelt AR, Wilkins S, Husband D, Haylock B. Molecular genetics, imaging and treatment of oligodendroglial tumours. Acta Neurochir. (Wien.)152(11),1815–1825 (2010).
- 17 Cairncross G, Berkey B, Shaw E et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J. Clin. Oncol.24(18),2707–2714 (2006).▪ Demonstrated that patients with oligodendrogliomas harboring the 1p/19q codeletion have improved surivival when compared to those without the codeletion, regardless of treatment paradigm.
- 18 Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer9(12),862–873 (2009).
